Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1233 participants.
Also called NCT02099110
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,233 participants
- Sponsor
- Registry
-
NCT02099110 -
2013-003698-82
-
- Main results
- Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02099110. Randomized; double masking; primary purpose treatment. Start 2014-04-22 (actual); primary completion 2016-05-26 (actual). Results posted on 2017-11-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Matching Placebo to Ertugliflozin 5 mg
- Intervention (Drug)
- Matching Placebo to Ertugliflozin 10 mg
- Intervention (Drug)
- Matching Placebo to sitagliptin 100 mg
- Intervention (Drug)
- Ertugliflozin 5 mg
- Intervention (Drug)
- Ertugliflozin 10 mg
- Intervention (Drug)
- Sitagliptin 100 mg
- Intervention (Drug)
- Metformin >= 1500 mg/day
- Intervention (Biological)
- Insulin Glargine Rescue Medication
- Intervention (Drug)
- Glimepiride Rescue Medication
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct02099110- Content hash
10eaef35b6c7cf829acdc93ed150d1676115e8d8dbdf0a81efd20fc6e867c99a